Business
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
WILMINGTON, Del., November 09, 2025--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the 24-hour period, including early morning, when patients wit
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1181,"height":286,"url":"https://media.zenfs.com/en/business-wire.com/b3ca07fc258a20462cb514e02fc5e084"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cS3k8g3BKXFajbG9g2g1Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b3ca07fc258a20462cb514e02fc5e084","width":960,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IIXmlUFQ3Lfwr7GZnQJqkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjI7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b3ca07fc258a20462cb514e02fc5e084","width":1181,"height":286}},"lazy":false},{"type":"image","alt":"Summary of results (1). Hourly Mean Systolic Blood Pressure at Week 12. Line graph presents mean and standard error.","displaySize":"","headline":null,"caption":"Summary of results (1). Hourly Mean Systolic Blood Pressure at Week 12. Line graph presents mean and standard error.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":387,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/810d545b3ad9f46d7fc6925f1f89e44f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wDrwixFb1tUlla2djL8d4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg3NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/810d545b3ad9f46d7fc6925f1f89e44f","width":387,"height":480}}},{"type":"text","content":"Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial","length":207,"tagName":"p","attribs":{}},{"type":"text","content":"Full results presented at the American Heart Association Scientific Sessions 2025","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., November 09, 2025--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the 24-hour period, i...